Delivery Order SPE2DB24D2105-SPE2DB24FAPPG

Award Date 7/2/24
Potential Completion Date 7/3/24
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,340.41 firm fixed-price delivery order is for the supply of Gemtesa 75 mg tablets. The contract has a completion date of July 17, 2024 and was awarded on July 16, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $11,101.12, is for the delivery of Gemtesa 75 mg tablets. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,601.91, is for the delivery of Gemtesa 75 mg tablets over a period ending on July 24, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $8,730.28, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, which has no set-aside designation, is a delivery order contract for the supply of GEMTESA 75 MG TABLET 90S, a medical product, with a completion date of December 12, 2024. In addition to this specific contract, AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $52,016.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GEMTESA 75 MG TABLET 90S, a medication, with a period of performance through January 21, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. The IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,138.89 firm fixed-price delivery order contract is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has a completion date of June 10, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp (a major pharmaceutical distributor) was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,203.98 firm fixed-price delivery order is for the supply of 4561390786 Gemtesa 75 mg tablets, with a completion date of July 3, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $3,290.43 and is for the delivery of GEMTESA 75 MG TABLET 90S, a medical product. The contract is a firm fixed-price Delivery Order, with an ultimate completion date of July 24, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,465.69 fixed-price delivery order contract is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with a completion date of December 30, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,151.80 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB24D2105
    Indefinite Delivery Contract
  • SPE2DB24D2105-SPE2DB24FAPPG
    Delivery Order

This federal contract award, valued at $17,204.23, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for Gemtesa 75 mg tablets, a medical product, and has a completion date of July 3, 2024.

The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. This specific award was not designated with a set-aside requirement, indicating open competition.

Generated 5/17/25, 9:42 AM